Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo)

Vokes, Natalie I.Gandara, David R.Sezer, AhmetKilickap, SaadettinGumus, MahmutBondarenko, IgorOzguroglu, Mustafa2024-05-192024-05-1920230732-183X1527-7755https://hdl.handle.net/20.500.12713/5974Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 02-06, 2023 -- Chicago, IL[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keywords]Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo)Conference Object4116WOS:001053772003690N/A